Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Smoking cessation

This article was originally published in The Tan Sheet

Executive Summary

Providing more "pharmacological options to smokers can increase the number of treatment-assisted quit attempts," CDC editors state in the July 28 Morbidity & Mortality Weekly Report. A study examining sales of Rx and OTC smoking cessation items - patches, gums, inhalers, nasal sprays and non-nicotine Rx drugs - shows the number of smokers attempting to quit using drug therapy increases when a new product is introduced and when existing products are switched to OTC status. Conducted at the University of Pittsburgh, the study was sponsored by Nicorette and NicoDerm CQ marketer SmithKline Beecham. The editors note the report is based on sales rather than actual usage, that Rx and OTC sales are not tallied the same way and that externalities such as cigarette price increases and public policy were not considered
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS091523

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel